➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Boehringer Ingelheim
Colorcon
Medtronic
Harvard Business School

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CS-3150

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CS-3150?

CS-3150 is an investigational drug.

There have been 11 clinical trials for CS-3150. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Hypertension, Renal Insufficiency, and Kidney Diseases. The leading clinical trial sponsors are Daiichi Sankyo Co., Ltd., Daiichi Sankyo Inc., and Daiichi Sankyo, Inc.

There are fourteen US patents protecting this investigational drug and one hundred and sixteen international patents.

Recent Clinical Trials for CS-3150
TitleSponsorPhase
Study of CS-3150 in Patients With Primary AldosteronismDaiichi Sankyo Co., Ltd.Phase 3
Study of CS-3150 in Patients With Essential HypertensionDaiichi Sankyo Co., Ltd.Phase 3
Study of CS-3150 Compared to Olmesartan in Patients With Essential HypertensionDaiichi Sankyo Co., Ltd.Phase 3

See all CS-3150 clinical trials

Clinical Trial Summary for CS-3150

Top disease conditions for CS-3150
Top clinical trial sponsors for CS-3150

See all CS-3150 clinical trials

US Patents for CS-3150

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CS-3150   Start Trial Method for producing pyrrole derivative, and intermediate thereof Daiichi Sankyo Company, Limited (Chuo-ku, JP)   Start Trial
CS-3150   Start Trial Solid composition of pyrrole carboxamide Daiichi Sankyo Company, Limited (Chuo-ku, JP)   Start Trial
CS-3150   Start Trial Pharmaceutical for prophylaxis or treatment of hypertension Daiichi Sankyo Company, Limited (Chuo-ku, JP)   Start Trial
CS-3150   Start Trial Method for producing pyrrole derivative, and intermediate thereof Daiichi Sankyo Company, Limited (Chuo-ku, JP)   Start Trial
CS-3150   Start Trial Pyrrole derivatives as pharmaceutical agents Exelixis, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CS-3150

Drugname Country Document Number Estimated Expiration Related US Patent
CS-3150 Canada 2922350 2033-08-27   Start Trial
CS-3150 China 105473552 2033-08-27   Start Trial
CS-3150 European Patent Office 3040330 2033-08-27   Start Trial
CS-3150 Spain 2660988 2033-08-27   Start Trial
CS-3150 Hungary E037007 2033-08-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Boehringer Ingelheim
Colorcon
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.